These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3266712)

  • 1. [Treatment of advanced cancer of the urinary tract with interleukin-2 (IL-2)].
    Hara M; Terashima Y; Kanamori S; Senga Y; Kondoh Y; Ohhara M; Tsuboi N; Nishimura T; Akimoto M
    Hinyokika Kiyo; 1988 Oct; 34(10):1693-6. PubMed ID: 3266712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
    Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
    Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
    Kilbourn RG; Fonseca GA; Trissel LA; Griffith OW
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S21-30. PubMed ID: 10685654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
    Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
    Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy of recombinant interleukin 2 in local treatment of superficial bladder tumors].
    Fujioka T; Shiraishi M; Tanji S; Sato S; Koike H; Aoki H; Suzuki K; Kumagai K; Banya Y; Kubo T
    Hinyokika Kiyo; 1988 Dec; 34(12):2115-9. PubMed ID: 3266444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Trials of immunotherapy in tumors of the urinary tract].
    Corrado F; Pizza G
    Arch Esp Urol; 1984 Dec; 37 Suppl 2():659-66. PubMed ID: 6336141
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.
    Webb DE; Austin HA; Belldegrun A; Vaughan E; Linehan WM; Rosenberg SA
    Clin Nephrol; 1988 Sep; 30(3):141-5. PubMed ID: 3263237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
    Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
    Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
    Marcus SL; Dutcher JP; Paietta E; Ciobanu N; Strauman J; Wiernik PH; Hutner SH; Frank O; Baker H
    Cancer Res; 1987 Aug; 47(15):4208-12. PubMed ID: 3496958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 immunotherapy in children.
    Chien CH; Hsieh KH
    Pediatrics; 1990 Dec; 86(6):937-43. PubMed ID: 2174536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Vetto JT; Seipp CA; Simpson C
    Surgery; 1986 Aug; 100(2):262-72. PubMed ID: 3526604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
    Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.
    Yasumoto K; Mivazaki K; Nagashima A; Ishida T; Kuda T; Yano T; Sugimachi K; Nomoto K
    Cancer Res; 1987 Apr; 47(8):2184-7. PubMed ID: 3493843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.